Taysha Gene Therapies (TSHA) Return on Capital Employed (2020 - 2026)

Taysha Gene Therapies has disclosed Return on Capital Employed across 7 years of filings, most recently posting 43.93% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 43.93%, up 2590.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 43.93% (up 2590.0% YoY), and the FY2025 annual result was 49.05%, up 1613.0% from the prior year.
• Return on Capital Employed came in at 43.93% for Q1 2026 at Taysha Gene Therapies, down from 36.42% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 263.57% in Q3 2023 to a low of 291.63% in Q2 2023.
• The 5-year median for Return on Capital Employed is 63.49% (2024), against an average of 89.39%.
• Across the five-year window, Return on Capital Employed surged 43230 bps in 2023 and tumbled 31810 bps in 2024, its largest moves.
• Taysha Gene Therapies' Return on Capital Employed stood at 289.66% in 2022, then soared by 83 bps to 49.11% in 2023, then dropped by 29 bps to 63.49% in 2024, then jumped by 43 bps to 36.42% in 2025, then declined by 21 bps to 43.93% in 2026.
• The last three Return on Capital Employed figures came in at 43.93% (Q1 2026), 36.42% (Q4 2025), and 34.47% (Q3 2025), per Business Quant data.